Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
7.03
-0.47 (-6.27%)
At close: Feb 27, 2026, 4:00 PM EST
6.86
-0.17 (-2.38%)
After-hours: Feb 27, 2026, 7:11 PM EST
Aligos Therapeutics Stock Forecast
ALGS's stock price has decreased by -60.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Aligos Therapeutics stock have an average target of 46.67, with a low estimate of 20 and a high estimate of 70. The average target predicts an increase of 563.87% from the current stock price of 7.03.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 7, 2026.
Analyst Ratings
The average analyst rating for Aligos Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +184.50% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +611.24% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +611.24% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +895.73% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $70 | Strong Buy | Maintains | $75 → $70 | +895.73% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
2.60M
from 3.95M
Decreased by -34.12%
Revenue Next Year
2.17M
from 2.60M
Decreased by -16.58%
EPS This Year
-8.50
from -20.94
EPS Next Year
-7.16
from -8.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.6M | 4.7M | ||||
| Avg | 2.6M | 2.2M | ||||
| Low | 2.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -9.5% | 81.8% | ||||
| Avg | -34.1% | -16.6% | ||||
| Low | -50.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -7.99 | -5.21 | ||||
| Avg | -8.50 | -7.16 | ||||
| Low | -8.87 | -8.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.